Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path ...
As of June 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $226.1 million, which provides projected cash runway into 2026. Second quarter of 2024 compared to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results